Physician profile
Ali Hammad
NPI 1154354892
$592.88
in general payments reported to CMS, 2019-2025
13 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.94 · 2020: $136 · 2021: $13.61 · 2022: $79.39 · 2023: $33.82 · 2024: $128 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $206.97 | 2020-2025 | Biomonitor, Amvia Edge |
| Pfizer INC. | $118.47 | 2022-2025 | |
| Boston Scientific Corporation | $40.68 | 2024-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.72 | 2022-2025 | Jardiance |
| Abiomed | $34.25 | 2024 | Impella |
| Abbott Laboratories | $33.83 | 2019-2021 | |
| Irhythm Technologies, INC. | $32.40 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Medtronic, INC. | $16.64 | 2024 | Corevalve Evolut R |
| Amgen INC. | $15.78 | 2022 | |
| Ge Healthcare | $14.68 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.